Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Prostatic Neoplasms

In brief

The purpose of this study is to evaluate the clinical benefit of the co-administration of propranolol and etodolac (VT-122 therapy) in patients with clinically progressive prostate cancer.

Key facts

Study ID

NCT01857817

Run by

Vicus Therapeutics

People needed

35

Starts

2013-06-01

Expected to finish

2016-04-01

Last updated by the study team

2018-04-26

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Have a confirmed diagnosis of prostate cancer
• Male participants who are ≥18 years of age
• In the opinion of the investigator, the participants have a life expectancy of at least 3 months.
• Two consecutively rising PSA values or two out of three rising PSA values (2.0 ng/mL is the minimum ending value for PSA) at a minimum of 1-week intervals
• Have a Karnofsky Performance Score (KPS) equal to or greater than 70
• Have the following laboratory parameters (may be assessed locally):
• Platelet count ≥50 x 10E3/µL
• Total bilirubin ≤1.5 mg/dL
• Serum creatinine ≤1.5 x upper limit of normal (ULN) or creatinine clearance >60 mL/min calculated using Cockcroft-Gault
• Liver enzymes [aspartate transaminase (AST), alanine transaminase (ALT)] ≤2 x ULN
• Able to provide written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, for any reason without prejudice

You may not qualify if…

• The patient has a history of another primary cancer, with the exception of:
• Curatively resected non-melanomatous skin cancer;
• Other primary solid tumor with no known active disease presents that in the opinion of the investigator that will not affect patient outcome in the setting of current prostate cancer diagnosis.
• Contraindication to propranolol, etodolac
• Patients on beta blockers
• Patients receiving chemotherapy (e.g., docetaxel, cabazitaxel, taxane, or platinum as single agents or in combination) as their cancer treatment
• History or evidence of cardiac disease: congestive heart failure; New York Heart Association class 2 or greater; active coronary artery disease; unstable angina, cardiac arrhythmias requiring anti-arrhythmic therapy, atrio-ventricular block of second or third degree, or uncontrolled hypertension, patients with recent (less than 6 months) myocardial infarction (MI) or coronary revascularization
• Hypotension at the time of screening (i.e., systolic blood pressure less than 110 mmHg. Diastolic blood pressure less than 60 mmHg)
• Resting heart rate less than 60 bpm at time of screening
• Any uncontrolled, intercurrent illness that in the opinion of the Investigator may interfere with study evaluation. Participants with uncontrolled diabetes will be excluded from the study.
• On chronotropic drugs (acetylcholine, digoxin, diltiazem, verapamil, atropine, dopamine, dobutamine, epinephrine, isoproterenol)
• Active clinically serious infections [> Grade 2 National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.0]
• Substance abuse, medical, psychological or social conditions that may, in the opinion of the investigator, interfere with the patient's participation in the study or evaluation of the study results
• Known or suspected allergy to the investigational agents or any agent given in association with this trial (hypersensitivity reaction, hives, rash, difficulty breathing swelling of your face, lips, tongue, or throat)
• Any condition that is unstable or which in the opinion of the Investigator could jeopardize the safety of the patient and his/her compliance in the study
• Patients with uncontrolled diabetes or insulin resistance
• Participation in any other investigational trial in which receipt of investigational drug or device occurred within 30 days prior to screening for this study

Where it is running

• Highlands Oncology Group — Fayetteville, Arkansas, United States
• Redwood Regional Medical Group — Santa Rosa, California, United States
• Advanced Urology — Parker, Colorado, United States
• Manatee Medical Research Institute, LLC — Bradenton, Florida, United States
• Baptist Cancer Institute — Jacksonville, Florida, United States
• Midwestern Regional Medical Center — Zion, Illinois, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• Detroit Clinical Research Center, PC — Lansing, Michigan, United States
• Adult & Pediatric Urology — Sartell, Minnesota, United States
• AccuMed Research Associates — Garden City, New York, United States
• Premier Medical Group of the Hudson Valley PC — Poughkeepsie, New York, United States
• Montefiore Medical Center — The Bronx, New York, United States
• Hendrick Cancer Center — Abilene, Texas, United States
• Oncology Consultants, P.A. — Houston, Texas, United States
• Virginia Mason Medical Center — Seattle, Washington, United States
• Medical Oncology Associates, PS — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.